New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS.
The evaluation of gene and protein expression profiles is a promising strategy to drive the therapeutical decision-making in non-small cell lung cancer (NSCLC). Among the several candidate genes that have been proposed, many retrospective studies have indicated excision repair cross-complementing 1 (ERCC1), an endonuclease responsible for the repair of DNA damages, as a reliable biomarker of tumor sensitivity to platinum-based agents. Moreover, the recent evidences showing the clinical efficacy of next-generation multitargeted antifolate drugs, in NSCLC, have highlighted the role of the determination of thymidylate synthase (TS) expression levels. Here is presented a brief overview of the literature regarding these two genes that are currently under prospective investigation as predictive markers of treatment efficacy in NSCLC.
Ceppi
P
P
Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. paolo.ceppi@unito.it
Papotti
M
M
Scagliotti
G
G
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D004720:Endonucleases / Q000235:genetics / Q000378:metabolism*; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D013940:Thymidylate Synthase / Q000235:genetics / Q000378:metabolism*
D004268:DNA-Binding Proteins; D005493:Folic Acid Antagonists; D013940:Thymidylate Synthase; C071447:ERCC1 protein, human; D004720:Endonucleases